On October 24, 2024, an advisory panel of the U.S. Centers for Disease Control and Prevention (CDC) voted to recommend lowering the pneumococcal vaccination age from 65 to 50 years old.
This recommendation applies to Merck's Capvaxive and Pfizer's Prevnar 20, significantly expanding the target population for these vaccines. The decision is expected to increase the market opportunity for Capvaxive.
The expanded recommendation underscores the importance of broader pneumococcal disease prevention in adults. This regulatory endorsement is a positive development for Merck's vaccine segment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.